MedTrace Logo

A Study to Evaluate the Safety and Effectiveness of Three Asoprisnil Doses in the Treatment of Women With Endometriosis

NCT00160446 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 130

Last updated 2008-05-29

No results posted yet for this study

Summary

The objective of this study is to determine the safety and effectiveness of three doses of asoprisnil, compared to placebo, in the treatment of women with endometriosis.

Conditions

  • Endometriosis

Interventions

DRUG

Asoprisnil

5mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

10 mg Tablet, oral Daily for 12 weeks

DRUG

Asoprisnil

25 mg Tablet, oral Daily for 12 weeks

DRUG

Placebo

Tablet, oral Daily for 12 weeks

Sponsors & Collaborators

Principal Investigators

  • Medical Director · Abbott

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2000-05-31
Primary Completion
2001-07-31
Completion
2001-07-31

More Related Trials

Entities

Drugs
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00160446 on ClinicalTrials.gov